Celcuity Inc. (NASDAQ:CELC – Get Free Report) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $29.00.
A number of research analysts have recently issued reports on CELC shares. Craig Hallum reiterated a “buy” rating and set a $27.00 target price (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a report on Thursday, August 15th. Stifel Nicolaus cut their price target on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Leerink Partnrs raised Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a report on Thursday, August 15th.
View Our Latest Stock Analysis on Celcuity
Hedge Funds Weigh In On Celcuity
Celcuity Trading Down 0.3 %
Shares of NASDAQ:CELC opened at $16.99 on Friday. The company has a quick ratio of 11.23, a current ratio of 11.23 and a debt-to-equity ratio of 0.28. Celcuity has a 52-week low of $8.39 and a 52-week high of $22.19. The business has a 50-day moving average price of $16.85 and a 200-day moving average price of $16.87. The stock has a market cap of $596.37 million, a price-to-earnings ratio of -6.11 and a beta of 0.81.
Celcuity (NASDAQ:CELC – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. During the same period in the previous year, the company posted ($0.66) earnings per share. Equities analysts predict that Celcuity will post -2.86 EPS for the current year.
About Celcuity
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Recommended Stories
- Five stocks we like better than Celcuity
- The Significance of Brokerage Rankings in Stock Selection
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- What Is WallStreetBets and What Stocks Are They Targeting?
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How to Invest in Blue Chip Stocks
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.